psoriasis model
Inflammation Models
Psoriasis Model
Psoriasis is a chronic skin condition triggered or exacerbated by a number of genetic, environmental and immunological factors. Characterised by hyperproliferation of keratinocytes, abnormal epidermal differentiation and infiltration of immune cells, the symptoms may vary but include soreness, red, raised or scaly patches of skin and itching. At Cellomatics, we offer a Psoriasis in vitro model which utilises human primary keratinocytes and freshly isolated immune cells to closely recapitulate the human condition, providing a high throughput drug screening platform.
Available formats
Standard 96-well format.
Alternative format offerings available upon request.
Pilot assay development is available as a standalone service, or as a built in checkpoint for full studies
FAQ's
Cellomatics offers a range of validated in vitro and ex vivo psoriasis models, including primary human keratinocyte cultures and advanced co-culture systems. These models are designed to recapitulate key features of psoriatic pathology, such as epidermal hyperplasia and inflammatory signalling.
These assays quantify disease-relevant endpoints such as keratinocyte proliferation, antimicrobial peptide expression, and pro-inflammatory cytokines including IL-17 and IL-23. This enables precise assessment of how compounds modulate psoriatic inflammation.
Yes. Co-culture systems incorporating immune cells, such as T cells, are used to model the cross-talk between immune and skin cells. This approach provides insight into mechanisms driving disease and therapeutic response. At Cellomatics, this is further strengthened by the use of freshly isolated immune cells through in-house blood collection and processing, ensuring high viability, physiological relevance, and more predictive data.
Cellomatics combines human primary cell models with robust assay design to generate high-quality, biologically relevant data. Study designs are tailored to align with specific project objectives and therapeutic mechanisms.
Yes. Assays can be customised to target specific signalling pathways or induction mechanisms, ensuring alignment with the mode of action of the therapeutic candidate.